MarketPulse

clinical trial safety concerns

4 articles
BenzingaBenzinga··The Law Offices Of Frank R. Cruz

SLNO Shareholders Sue Over Alleged Safety Disclosure Failures in PWS Drug Trial

Soleno Therapeutics faces securities fraud lawsuit alleging failure to disclose safety concerns about DCCR drug candidate between March 2025 and November 2026.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Securities Lawsuit Over Undisclosed Safety Risks in DCCR Trial

Rosen Law Firm files class action against Soleno Therapeutics for allegedly concealing fluid retention safety concerns in DCCR clinical trials, affecting drug viability.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Soleno Therapeutics Faces Class Action Over DCCR Safety Claims as Stock Plummets 27%

Robbins LLP launches class action against $SLNO over alleged investor deception regarding DCCR drug safety and efficacy for Prader-Willi syndrome treatment.
EOSEDRVNSLNOclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Soleno Therapeutics Faces Securities Fraud Probe Over Undisclosed Safety Data

Law firm probing Soleno Therapeutics for allegedly concealing safety data on drug DCCR. Investors must file claims by May 5, 2026.
SLNOstock declinesecurities class action